• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Macro Australian Economy

Imugene [ASX:IMU] Receives US Patent for PD1-Vaxx

Like 0

By Mahlia Stewart, Friday, 10 February 2023

Imugene shares rise 11% for new US patent relating to its lung cancer vaccination currently in clinical development.

Reporting from Sydney this morning, clinical-stage cancer immunotherapy developer Imugene [ASX:IMU] made the upbeat announcement that it now has a patent to treat patients in the US.

A Notice of Allowance from the US Patent and Trademark Office (USPTO) has been passed for the B-cell activating immunotherapy PD1-Vaxx, which is currently in clinical development for non-small cell lung cancer (NSCLC).

IMU shareholders were showing their support for the latest development, upping the stock price to 15 cents a piece by the early afternoon on Friday, an increase of more than 11%.

Imugene’s shares may have dropped 54% over the past 52-week cycle, and it’s still down 63% in its sector, but the result today has given it a 3.5% boost so far in the year and brought it up 7% in the last week.

ASX:IMU stock ticker

Source: tradingview.com

Imugene marks US milestone for PD1-Vaxx

A week after announcing its Phase 1 MAST cancer-combating study for VAXINIA passed cohort 2 of monotherapy trials — and after treating its first patient in December — the biotech brought another win to the foreground in sharing news of its acceptance for the use of PH1-Vaxx in the US.

Imugene says that its B-cell activating immunotherapy PD1-Vaxx, which treats non-small cell lung cancer (NSCLC), has received a Notice of Allowance from the US Patent and Trademark Office (USPTO).

The patent, titled ‘Human PD1 Peptide Vaccines and Uses Thereof’ basically represents clearance, ownership and protection for Imugene to use its PD1-Vaxx as a method of treatment in cancer while targeting antibody response against the programmed death-1 (PD1) checkpoint target, up until 2038.

Imugene said that it is now reaching final preparations for clinical trials which combine PD1-Vaxx with atezolizumab (Tecentriq®), an immune checkpoint inhibitor that targets PD-L1, in patients with NSCLC.

PD-L1 is a protein that lets cells escape attacks created by the immune system, a process often compromised by other proteins interfering with the body’s natural healing responses.

Checkpoint inhibitor drugs — like Tecentriq® — prevent the block from happening, allowing the immune system to attack tumour cells freely.

Imugene can now determine the safety, efficacy, and optimal dosage of PD1-Vaxx in combination with atezolizumab as a first-line therapy in NSCLC patients in Australia and the US — opening it up to wider opportunities and market share while also helping one more cancer patient at a time.

Leslie Chong, Imugene’s MD & CEO commented:

‘It’s vital to our business that we continue locking in intellectual property protection across the portfolio of assets, and I am proud to continue to strengthen our IP. With the US being the largest healthcare market in the world, this is a particularly important patent to protect our PD1-Vaxx technology as we continue its development.’

Australia’s commodity boom looms

Biotech is a very important industry for Australia, but have you thought about Australia’s biggest industries? Some of the most exported, most lucrative resources that brings in most of the economy’s capital?

Our in-house resources expert and trained geologist, James Cooper, thinks the Australian resources sector is set to enter a new commodities boom brought on by the ‘Age of Scarcity’.

James is convinced ‘the gears are in motion for another multi-year boom in commodities’…and better yet, this is a boom where Australia and its stocks stand to benefit greatly.

The next big mining boom is predicted to happen in the next few years, and the question is, are you ready for it?

Don’t let the same people who got rich last time be the only ones for a second time!

You can access a recent report by James on exactly that topic, AND access an exclusive video on his personalised ‘attack plan’ — right here.

 

Regards,

Mahlia Stewart,

For The Daily Reckoning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Mahlia Stewart

Mahlia’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Trump Sparks Rare Earth Rally
    By Murray Dawes

    Murray and Callum pointed out three lithium stocks last week that surged 5–12% this week. Now they look at copper and rare earths.

  • Copper Breaks Out: Are You Positioned?
    By James Cooper

    Last week, James Cooper wrote about the need to be on high alert for a copper breakout. This week, copper is breaking out… James lays out the game plan from here.

  • A radically innovative industry set to soar
    By Callum Newman

    Pretty soon we’re going to have flying transportation. It could cut car travel demand again. See below for my moonshot idea on this.

Primary Sidebar

Latest Articles

  • Trump Sparks Rare Earth Rally
  • Copper Breaks Out: Are You Positioned?
  • A radically innovative industry set to soar
  • Debt and declining demographics are a dangerous combination
  • Critical Metal Stocks: Following the Iron Ore Playbook

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988